{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Iodine_I_131_MIP-1095",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioconjugate composed of MIP-1095, a urea-based ligand for the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) radiolabeled with iodine I 131 (I131), with potential antineoplastic activity. Upon administration of iodine I 131 MIP-1095, the MIP-1095 moiety selectively targets and binds to the extracellular domain of PSMA, thereby delivering cytotoxic iodine I 131 specifically to PSMA-expressing cancer cells. PSMA is a transmembrane glycoprotein that is highly expressed by malignant prostate epithelial cells and certain other tumor cells.",
    "fdaUniiCode": "7DM27RQ9V0",
    "identifier": "C131821",
    "preferredName": "Iodine I 131 MIP-1095",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129819",
      "C2124"
    ],
    "synonyms": [
      "((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(131)I]iodophenyl)ureido)pentyl)ureido)pentanedioic Acid",
      "(131) I-MIP-1095",
      "131I-MIP-1095",
      "I-131 MIP-1095",
      "Iodine I 131 MIP-1095",
      "MIP-1095 I-131"
    ]
  }
}